Detailed Information

Cited 22 time in webofscience Cited 24 time in scopus
Metadata Downloads

PPAR gamma Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis

Authors
Han, Jee-YoungKim, Ye-JiKim, LuciaChoi, Suk-JinPark, In-SuhKim, Joon-MeeChu, Young ChaeCha, Dae-Ryong
Issue Date
Jan-2010
Publisher
KOREAN ACAD MEDICAL SCIENCES
Keywords
PPAR gamma; Receptors; Angiotensin; Fibrosis; Plasminogen Activator Inhibitor 1; Transforming Growth Factor Beta
Citation
JOURNAL OF KOREAN MEDICAL SCIENCE, v.25, no.1, pp.35 - 41
Indexed
SCIE
SCOPUS
KCI
Journal Title
JOURNAL OF KOREAN MEDICAL SCIENCE
Volume
25
Number
1
Start Page
35
End Page
41
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15242
DOI
10.3346/jkms.2010.25.1.35
ISSN
1011-8934
Abstract
The peroxisome proliferator activated receptor (PPAR)gamma agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPAR gamma agonist and interaction with angiotensin receptor antagonist in the unilateral ureteral obstruction (UUO) model. After UUO, mice were divided to four groups: no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+ pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and p-Smad2 demonstrated that their expressions were increased in CONT group and decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group. The expression of TGF-beta 1 from real time RT PCR showed markedly increased in the CONT group and decreased in all treated groups compared to CONT. These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the synergism between pioglitazone and L158809 is not clear. Considering decreased expression of PAI-1 and TGF-beta/Smad2 in the treated groups, PAI-1 and TGF-beta are likely linked to the decreased renal tubulointerstitial fibrosis. According to these results, the PPAR gamma agonist might be used in the treatment of renal fibrotic disease.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Nephrology and Hypertension > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Cha, Dae Ryong photo

Cha, Dae Ryong
Ansan Hospital (Department of Nephrology and Hypertension, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE